Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted fast track designation to Dara BioSciences' KRN5500 to treat cancer patients with chemotherapy-induced neuropathic pain.
Subscribe to our email newsletter
The company has previously released positive results from a Phase II (DTCL100) trial evaluating KRN5500, which demonstrated reduction of pain and safety and was superior to placebo.
Based largely on these positive findings, the National Cancer Institute (NCI) is partnering with Dara to initiate a second Phase II study, which it anticipates will commence later this year.
Dara chairman and CEO Richard Franco said the FDA fast track designation for KRN5500 is a significant positive step for the thousands of cancer patients who suffer this unremitting pain from a number of causes including from their chemotherapy.